---
name: medlog→OTel panel (SEC/SRE/FIN) per-point response on Deep×2
description: 2026-05-15 panel cross-review of Deep×2 medlog→OTel; 0 CHALLENGE bidirectional, ~38 AGREE / ~10 SYNTHESIZE / 6 panel-unique; sequenced verdict stable
type: project
originSessionId: c5fc3072-0da2-4036-9fd4-0491da242fed
---
2026-05-15 — Panel of 3 role-specific reviewers (Security / SRE / Finance) per-point AGREE/CHALLENGE/SYNTHESIZE on Deep×2 medlog→OTel review. ~41st stacked-COI case overall.

**Convergence summary**:
- 0 CHALLENGE bidirectional across all Deep points (COI, F1–F6, A1–A5, B1–B7, C1–C3, D1–D3, E1–E4, F1–F3, G1–G3, H verdict).
- ~38 AGREE, ~10 SYNTHESIZE (severity/specificity sharpenings — notably B3 cardinality, B6 request-context rules, C3 onboarding MED→HIGH, E3 decompose-as-stage-gated-funding).
- **6 panel-unique findings** the COI Deep seat did not surface:
  1. Audit-system access controls (Grafana defaults not HIPAA-ready) — SEC MED
  2. WORM/immutability/hash-chain for 6yr retention — SEC MED, gap in both stacks
  3. OTel collector operational expertise gap — SRE MED
  4. Loss-expectancy framing ($100K–$1.5M per HIPAA reportable event) — FIN HIGH, justifies $45–100K gate spend at any plausible probability
  5. 6-year retention TCO comparison Loki vs ES — FIN MED, required line item
  6. Kafka topic ACL enforcement on current medlog — SEC MED, finding against current stack independent of migration

**Key cost recalibrations**:
- Deep total ($30–80K) under-counts Phase 3 30-day spike. FIN panel revises to **$45–100K** before migrate decision (adds $15–30K for spike infra + engineer-month).
- Pay-Daniel-to-author-14-rules-as-discrete-deliverable should be Phase 0 first line item (~$5–10K), not a mitigation. Highest-leverage spend in plan.
- Strictly positive EV at any audit-failure probability ≥5%/12mo (panel estimate materially higher given 75% recent failure rate).

**Verdict stable across now ~41 stacked-COI cases / 9 domains**: sequenced stabilise → extract-14-rules → external-HIPAA-review → conditional-migrate, with **recuse-of-3** (Daniel + junior proposer + Deep-author-mentee) load-bearing. **Remaining question is organisational channel**: who has authority to enforce recusal and ensure external HIPAA reviewer's signoff supersedes Daniel's on equivalence test. Identical structural pattern to PG-optim, SaaS-cells, auth-v1, and prior medlog passes.

**Strongest single Deep-point**: A3 (Daniel's "never paged for audit failure" is self-undermining since he was paged for 3 of last 4).
**Strongest panel-unique**: FIN #4 loss-expectancy framing — converts the spend question from "is $50K worth it?" to "is the loss-EV math positive at p≥5%?"
